Evidence map›Paper›PMID 37286142›Full record

ArticleBiochimica et biophysica acta. Molecular basis of disease2023

The BDNF mimetic R-13 attenuates TBI pathogenesis using TrkB-related pathways and bioenergetics.

Pavan Thapak, Gregory Smith, Zhe Ying, Afshin Paydar, Neil Harris, Fernando Gomez-Pinilla

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta. Molecular basis of disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Anxiolytic Action of Dipeptide Mimetic of the BDNF Loop 2 in Adult Animals.Bulletin of experimental biology and medicine · 2024
    Article
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pavan ThapakDept. Integrative Biology and Physiology, UCLA, Los Angeles, CA, United States of America.
Gregory SmithDepartment of Neurosurgery, UCLA David Geffen School of Medicine, Los Angeles, CA, United States of America; UCLA Brain Injury Research Center, Los Angeles, CA, United States of America.
Zhe YingDept. Integrative Biology and Physiology, UCLA, Los Angeles, CA, United States of America.
Afshin PaydarDepartment of Neurosurgery, UCLA David Geffen School of Medicine, Los Angeles, CA, United States of America; UCLA Brain Injury Research Center, Los Angeles, CA, United States of America.
Neil HarrisDepartment of Neurosurgery, UCLA David Geffen School of Medicine, Los Angeles, CA, United States of America; UCLA Brain Injury Research Center, Los Angeles, CA, United States of America; Intellectual Development and Disabilities Research Center, University of California at Los Angeles, Los Angeles, CA 90095, USA.
Fernando Gomez-PinillaDept. Integrative Biology and Physiology, UCLA, Los Angeles, CA, United States of America; Department of Neurosurgery, UCLA David Geffen School of Medicine, Los Angeles, CA, United States of America; UCLA Brain Injury Research Center, Los Angeles, CA, United States of America. Electronic address: fgomezpi@ucla.edu.
University of California, Los Angeles · US

Funding

Strategy to Potentiate Rehabilitation after TBIR01NS116383 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HARRIS, NEIL · 2021 to 2025
$3.0M
Precision Medicine Approach: Using genomic information to guide TBI treatmentR01NS111378 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOMEZ-PINILLA, FERNANDO, YANG, XIA · 2020 to 2024
$2.9M
Spatiotemporal Molecular Substrates of TBI at Single Cell ResolutionR01NS117148 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GOMEZ-PINILLA, FERNANDO, WOLLMAN, ROY · 2020 to 2024
$2.8M
NINDS NIH HHS R01 NS111378NINDS NIH HHS R01 NS116383NINDS NIH HHS R01 NS117148
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is major neurological burden globally, and effective treatments are urgently needed. TBI is characterized by a reduction in energy metabolism and synaptic function that seems a primary cause of neuronal dysfunction. R13, a small drug and BDNF mimetic showed promising results in improving spatial memory and anxiety-like behavior after TBI. Additionally, R13 was found to counteract reductions in molecules associated with BDNF signaling (p-TrkB, p-PI3K, p-AKT), synaptic plasticity (GluR2, PSD95, Synapsin I) as well as bioenergetic components such as mitophagy (SOD, PGC-1α, PINK1, Parkin, BNIP3, and LC3) and real-time mitochondrial respiratory capacity. Behavioral and molecular changes were accompanied by adaptations in functional connectivity assessed using MRI. Results highlight the potential of R13 as a therapeutic agent for TBI and provide valuable insights into the molecular and functional changes associated with this condition.

Indexed as

Brain-Derived Neurotrophic FactorBrain Injuries, TraumaticEnergy MetabolismHumansMitochondriaSignal TransductionBrain-Derived Neurotrophic FactorBrain-derived neurotrophic factor (BDNF)Fluid percussion injuryMitochondrial bioenergeticsMitophagySynaptic plasticityTropomyosin receptor kinase B (TrkB)

Identifiers

PMID37286142
PMCPMC10619508
OpenAlexW4379374091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.